Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Share-based Compensation (2021 - 2025)

PAVmed (PAVM) has 5 years of Share-based Compensation data on record, last reported at $383000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation changed N/A year-over-year to $383000.0; the TTM value through Sep 2025 reached $2.2 million, changed N/A, while the annual FY2024 figure was $6.4 million, 42.1% down from the prior year.
  • Share-based Compensation reached $383000.0 in Q3 2025 per PAVM's latest filing, up from $162000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.2 million in Q2 2021 and bottomed at $162000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $2.9 million, with a median of $2.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 235.24% in 2022, then tumbled 91.49% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.4 million in 2021, then rose by 12.99% to $4.9 million in 2022, then crashed by 60.23% to $2.0 million in 2023, then crashed by 62.75% to $733000.0 in 2024, then crashed by 47.75% to $383000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $383000.0 in Q3 2025, $162000.0 in Q2 2025, and $930000.0 in Q1 2025.